Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 11 781 / https://doi.org/10.3332/ecancer.2017.781

Clinical Study

Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents

Chloroquine (CQ) and hydroxychloroquine (HCQ) are well-known 4-aminoquinoline antimalarial agents. Scientific evidence also supports the use of CQ and HCQ in the treatment of cancer. Overall, preclinical studies support CQ and HCQ use in anti-cancer therapy, especially in combination with conventional anti-cancer treatments since they are able to sensitise tumour cells to a variety of drugs, potentiating the therapeutic activity. Thus far, clinical results are mostly in favour of the repurposing of CQ. However, over 30 clinical studies are still evaluating the activity of both CQ and HCQ in different cancer types and in combination with various standard treatments. Interestingly, CQ and HCQ exert effects both on cancer cells and on the tumour microenvironment. In addition to inhibition of the autophagic flux, which is the most studied anti-cancer effect of CQ and HCQ, these drugs affect the Toll-like receptor 9, p53 and CXCR4-CXCL12 pathway in cancer cells. In the tumour stroma, CQ was shown to affect the tumour vasculature, cancer-associated fibroblasts and the immune system. The evidence reviewed in this paper indicates that both CQ and HCQ deserve further clinical investigations in several cancer types. Special attention about the drug (CQ versus HCQ), the dose and the schedule of administration should be taken in the design of new trials.

Keywords: Repurposing Drugs in Oncology (ReDO) project, drug repositioning, chloroquine (CQ), hydroxychloroquine (HCQ), neoplasms, antineoplastic agents, anti-malarial agents

Loading Article Metrics ... Please wait

Related articles

Review: Innovative approaches for cancer treatment: current perspectives and new challenges

Abstract | Full Article | PDF Published: 10 Sep 2019 / https://doi.org/10.3332/ecancer.2019.961

Case Report: Acute myeloid leukaemia presenting as acute liver failure—a case report and literature review

Abstract | Full Article | PDF Published: 09 Sep 2019 / https://doi.org/10.3332/ecancer.2019.960

Review: Holistic view of patients with melanoma of the skin: how can health systems create value and achieve better clinical outcomes?

Abstract | Full Article | PDF Published: 27 Aug 2019 / https://doi.org/10.3332/ecancer.2019.959

Review: Non-gastrointestinal stromal tumours soft tissue sarcomas: an update

Abstract | Full Article | PDF Published: 13 Aug 2019 / https://doi.org/10.3332/ecancer.2019.958

Clinical Study: Early toxicity and treatment outcomes of extended field-intensity modulated radiotherapy for cervical cancer patients with para-aortic nodal metastasis

Abstract | Full Article | PDF Published: 06 Aug 2019 / https://doi.org/10.3332/ecancer.2019.957



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation